

# Jennifer A Woyach

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4025508/publications.pdf>

Version: 2024-02-01

108  
papers

7,694  
citations

147801

31  
h-index

53230

85  
g-index

109  
all docs

109  
docs citations

109  
times ranked

6798  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. <i>Leukemia</i> , 2022, 36, 1171-1175.	7.2	72
2	A CAPTIVATE-ing new regimen for CLL. <i>Blood</i> , 2022, 139, 3229-3230.	1.4	1
3	NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 622-634.	4.9	33
4	Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib. <i>Leukemia</i> , 2022, 36, 2129-2131.	7.2	3
5	Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 716-721.	1.3	3
6	Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2021, 14, 17.	17.0	31
7	Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL. <i>Journal of Hematology and Oncology</i> , 2021, 14, 36.	17.0	9
8	Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients. <i>Leukemia</i> , 2021, 35, 3287-3290.	7.2	0
9	Acalabrutinib in treatment-naive chronic lymphocytic leukemia. <i>Blood</i> , 2021, 137, 3327-3338.	1.4	47
10	A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 766-774.	0.4	4
11	Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. <i>Leukemia</i> , 2021, 35, 2854-2861.	7.2	12
12	Abstract CT244: A Phase 1/2 study evaluating the safety and efficacy of IOV-2001 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). , 2021, , .		0
13	Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 3278-3282.	1.3	7
14	Genomics of Resistance to Targeted Therapies. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 715-724.	2.2	1
15	Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition. <i>Cancer Research Communications</i> , 2021, 1, 79-89.	1.7	6
16	Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021, 12, 6338.	12.8	3
17	Targeting Venetoclax-Resistant CLL By Bcl-XL Degradation. <i>Blood</i> , 2021, 138, 2252-2252.	1.4	0
18	Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients. <i>Cell and Bioscience</i> , 2021, 11, 197.	4.8	32

#	ARTICLE	IF	CITATIONS
19	Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study. <i>Blood</i> , 2021, 138, 392-392.	1.4	15
20	Characterization of LP-118, a Novel Small Molecule Inhibitor of Bcl-2 and Bcl-Xl in Chronic Lymphocytic Leukemia Resistant to Venetoclax. <i>Blood</i> , 2021, 138, 679-679.	1.4	5
21	Performance of Standard Prognostic Models in Older Adults Receiving Ibrutinib for Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL): A Post Hoc Analysis of Alliance A041202 Phase 3 Trial. <i>Blood</i> , 2021, 138, 2642-2642.	1.4	5
22	Does the cancer geriatric assessment (GA) introduce bias into clinical trials? Observations from 988 prospectively recruited patients. <i>Journal of Geriatric Oncology</i> , 2021, , .	1.0	1
23	T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 7-15.	2.0	37
24	Characterization and mitigation of fragmentation enzyme-induced dual stranded artifacts. <i>NAR Genomics and Bioinformatics</i> , 2020, 2, lqaa070.	3.2	8
25	Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 3626-3637.	1.6	71
26	Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 6187-6195.	7.0	3
27	Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry. <i>Nature Communications</i> , 2020, 11, 4268.	12.8	112
28	Targeting phosphatidylinositol 3 kinase- $\hat{1}^2$ and - $\hat{1}$ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4382-4392.	5.2	18
29	Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Cancer Discovery</i> , 2020, 10, 394-405.	9.4	60
30	Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naïve chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1278-1291.	13.7	393
31	BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072091299.	2.5	10
32	Current Perspectives on Therapy for Chronic Lymphocytic Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 320-329.	3.8	16
33	Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib. <i>Blood</i> , 2020, 136, 32-33.	1.4	6
34	Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Blood</i> , 2020, 136, 2-3.	1.4	1
35	Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 9-10.	1.4	12
36	Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 22-23.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Evaluation of the Incidence and Risk Factors Associated with Major Cardiovascular Events in Patients Receiving Acalabrutinib Therapy. <i>Blood</i> , 2020, 136, 29-30.	1.4	1
38	Use of <sc>PD</sc>1 (<sc>PDCD</sc>1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre. <i>British Journal of Haematology</i> , 2019, 185, 363-366.	2.5	22
39	Contemporary impacts of a cancer diagnosis on survival following in-hospital cardiac arrest. <i>Resuscitation</i> , 2019, 142, 30-37.	3.0	14
40	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 1353-1363.	4.1	305
41	Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib. <i>British Journal of Haematology</i> , 2019, 187, 399-402.	2.5	10
42	E $\frac{1}{4}$ -TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 6260-6273.	7.0	17
43	Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. <i>Leukemia</i> , 2019, 33, 2527-2530.	7.2	65
44	Representation of Patients With Cardiovascular Disease in Pivotal Cancer Clinical Trials. <i>Circulation</i> , 2019, 139, 2594-2596.	1.6	31
45	HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics. <i>Leukemia and Lymphoma</i> , 2019, 60, 2308-2311.	1.3	5
46	Treatment-naïve CLL: lessons from phase 2 and phase 3 clinical trials. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 476-481.	2.5	3
47	Hypertension and incident cardiovascular events following ibrutinib initiation. <i>Blood</i> , 2019, 134, 1919-1928.	1.4	155
48	Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy. <i>Blood</i> , 2019, 134, 3045-3045.	1.4	1
49	A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 3049-3049.	1.4	2
50	Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial). <i>Blood</i> , 2019, 134, 1754-1754.	1.4	7
51	Role of Mutant p53 in the Progression of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 2526-2526.	1.4	1
52	LC-Facseq: A Novel Method for Detecting Rare Resistant Clones in Leukemia. <i>Blood</i> , 2019, 134, 3377-3377.	1.4	0
53	The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 2077-2077.	1.4	1
54	BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor. <i>Cancer Discovery</i> , 2018, 8, 458-477.	9.4	101

#	ARTICLE	IF	CITATIONS
55	Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 1461-1465.	1.3	2
56	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. <i>New England Journal of Medicine</i> , 2018, 379, 2517-2528.	27.0	706
57	The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. <i>Cancer Discovery</i> , 2018, 8, 1300-1315.	9.4	115
58	How I manage ibrutinib-refractory chronic lymphocytic leukemia. <i>Blood</i> , 2017, 129, 1270-1274.	1.4	44
59	The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 2831-2841.	7.0	123
60	The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia. <i>Cancer Medicine</i> , 2017, 6, 778-787.	2.8	15
61	Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. <i>Blood Advances</i> , 2017, 1, 1739-1748.	5.2	123
62	Ibrutinib treatment improves T cell number and function in CLL patients. <i>Journal of Clinical Investigation</i> , 2017, 127, 3052-3064.	8.2	280
63	Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center. <i>Blood</i> , 2017, 130, 830-830.	1.4	27
64	Targeting BTK through microRNA in chronic lymphocytic leukemia. <i>Blood</i> , 2016, 128, 3101-3112.	1.4	30
65	Secondary autoimmune cytopenias in chronic lymphocytic leukemia. <i>Seminars in Oncology</i> , 2016, 43, 300-310.	2.2	26
66	Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. <i>Blood</i> , 2016, 127, 1117-1127.	1.4	381
67	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 323-332.	27.0	785
68	Chronic Lymphocytic Leukemia and Other Lymphoproliferative Disorders. <i>Clinics in Geriatric Medicine</i> , 2016, 32, 175-189.	2.6	7
69	Inhibitors of Bruton's Tyrosine Kinase Reduce Anti-Red Blood Cell Response in a Murine Model of Autoimmune Hemolytic Anemia. <i>Blood</i> , 2016, 128, 1259-1259.	1.4	5
70	Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center. <i>Blood</i> , 2016, 128, 2040-2040.	1.4	2
71	Role of Histone Deacetylase-Mediated Gene Silencing in Chronic Lymphocytic Leukemia Progression. <i>Blood</i> , 2016, 128, 2705-2705.	1.4	1
72	The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 3232-3232.	1.4	16

#	ARTICLE	IF	CITATIONS
73	Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism. <i>Blood</i> , 2016, 128, 3238-3238.	1.4	5
74	Natural History of Non-Infectious, Ibrutinib-Attributable Adverse Events Leading to Alternative BTK Inhibitor Use in CLL. <i>Blood</i> , 2016, 128, 4385-4385.	1.4	2
75	Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter's Transformation or Ibrutinib for Patients with Ibrutinib-Resistant Clones. <i>Blood</i> , 2016, 128, 4386-4386.	1.4	2
76	Major Bleeding Complications Among Patients Treated with Ibrutinib and Concomitant Antiplatelet, Anticoagulant, or Supplemental Therapy. <i>Blood</i> , 2016, 128, 4387-4387.	1.4	8
77	A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features. <i>Blood</i> , 2016, 128, 4388-4388.	1.4	2
78	REDX08608, a Novel, Potent and Selective, Reversible BTK Inhibitor with Efficacy and Equivalent Potency Against Wild-Type and Mutant C481S BTK. <i>Blood</i> , 2016, 128, 4399-4399.	1.4	4
79	the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL. <i>Blood</i> , 2016, 128, 55-55.	1.4	8
80	Phase 1b Results of a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2016, 128, 639-639.	1.4	22
81	Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. <i>Blood</i> , 2016, 128, 3198-3198.	1.4	0
82	Exploring the Functional Relevance of BTK Beyond Chronic Lymphocytic Leukemia (CLL) Cells: BTK Expression in Non-Malignant Immune Cells of the Microenvironment Mediates CLL Development and Progression In Vivo. <i>Blood</i> , 2016, 128, 352-352.	1.4	1
83	Patterns of resistance to B cell receptor pathway antagonists in chronic lymphocytic leukemia and strategies for management. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 355-360.	2.5	20
84	OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. <i>Blood</i> , 2015, 125, 284-295.	1.4	19
85	Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. <i>Blood</i> , 2015, 126, 842-850.	1.4	125
86	Targeted therapies in CLL: mechanisms of resistance and strategies for management. <i>Blood</i> , 2015, 126, 471-477.	1.4	112
87	Jumping translocations, a novel finding in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2015, 170, 200-207.	2.5	8
88	Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. <i>JAMA Oncology</i> , 2015, 1, 80.	7.1	498
89	Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2015, 21, 3705-3715.	7.0	183
90	Targeting BTK By a microRNA Mechanism in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 1232-1232.	1.4	1

#	ARTICLE	IF	CITATIONS
91	The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 2920-2920.	1.4	7
92	Ibrutinib Treatment Reduces Both T-Regulatory Cells and B-Regulatory Cell Phenotype in Malignant B Cells in Chronic Lymphocytic Leukemia Patients. <i>Blood</i> , 2015, 126, 2940-2940.	1.4	3
93	A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015, 126, 2953-2953.	1.4	2
94	A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and In Vitro Potency in B-Cell Malignancies. <i>Blood</i> , 2015, 126, 318-318.	1.4	0
95	Next Generation XPO1 Inhibitor Shows Improved Efficacy and In Vivo Tolerability in Hematologic Malignancies. <i>Blood</i> , 2015, 126, 317-317.	1.4	1
96	The Eμ-Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing. <i>Blood</i> , 2015, 126, 2752-2752.	1.4	8
97	Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib. <i>New England Journal of Medicine</i> , 2014, 370, 2286-2294.	27.0	1,042
98	A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. <i>Blood</i> , 2014, 124, 3553-3560.	1.4	56
99	Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). <i>Blood</i> , 2014, 123, 1207-1213.	1.4	176
100	Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. <i>Blood</i> , 2014, 123, 1810-1817.	1.4	246
101	Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype. <i>Blood</i> , 2013, 122, 2872-2872.	1.4	0
102	OSU-T315, An Integrin-Linked Kinase (ILK) Inhibitor, Induces Apoptosis By Targeting B Cell Receptor and CD49d Mediated AKT/ERK Activation In Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2013, 122, 2523-2523.	1.4	0
103	The B-cell receptor signaling pathway as a therapeutic target in CLL. <i>Blood</i> , 2012, 120, 1175-1184.	1.4	348
104	Translating PI3K-Delta Inhibitors to the Clinic in Chronic Lymphocytic Leukemia: The Story of CAL-101 (GS1101). <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 691-694.	3.8	8
105	Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712. <i>Journal of Clinical Oncology</i> , 2011, 29, 1349-1355.	1.6	124
106	Response, Progression-Free Survival, and Overall Survival of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities. <i>Blood</i> , 2010, 116, 2456-2456.	1.4	1
107	New therapeutic advances in the management of progressive thyroid cancer. <i>Endocrine-Related Cancer</i> , 2009, 16, 715-731.	3.1	42
108	Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 164-170.	3.6	142